NX 1607 New
Chemical Name: 2,3-Dihydro-2-[3-[cis-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)-1H-isoindol-1-one
Purity: ≥98%
Biological Activity
NX 1607 (Cbl-b-IN-3) is an inhibitor of CBL-B (Casitas B-lineage lymphoma proto-oncogene B), a RING-type E3 ubiquitin ligase. NX 1607 acts as an intramolecular glue. In vitro, NX 1607 activates MAPK/ERK signaling pathway and enhances T-cell activation in primary T cells and Jurkat T cells. In vivo, NX 1607 decreases tumor growth in cell lymphoma models. NX 1607 is orally bioavailable.Technical Data
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Additional Information
Product Datasheets
FAQs
No product specific FAQs exist for this product, however you may
View all Small Molecule FAQsReviews for NX 1607
There are currently no reviews for this product. Be the first to review NX 1607 and earn rewards!
Have you used NX 1607?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
